General Archives - Gilde Healthcare

Menu
Menu
Home

latest
news

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of Cardiology’s 73rd Annual Scientific Congress in Atlanta, GA this week. The data was also released online, ahead of print, in a simultaneous manuscript in the...
April 11, 2024

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

test ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a ‘stent-like’ expander designed to  gently ‘open-up’ the obstructed urethra and alleviate […]

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

test Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation Infrastructure Fund I. Gilde Healthcare invested in and, together with the founders, set-up RAD-x in 2016. Since its inception and […]

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and...

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent Life Sciences (U.K.) and Earlybird Venture Capital (Germany), as well as an...

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued...

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld as Chairman

The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology....

Gilde portfolio company LAVA Therapeutics announces collaboration with Merck & Co

LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207, a Gammabody® designed to target the prostate-specific membrane antigen...

Amphista Therapeutics announces in vivo efficacy and CNS activity of its protein degraders

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant...
Loading...
These were all messages
0d499d81b4